Navigation Links
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/7/2008

ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference, which is being held November 10-12, 2008 at the New York Palace Hotel in New York, NY. Mr. Burns' presentation is scheduled for Tuesday, November 11, 2008 at 2:25 p.m. (local time).

Mr. Burns' presentation will be web cast and, as previously announced, will serve as the Company's third quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)... Julian Whitaker, MD, a founder of...d expert on searchjointpain.com, a new information...scle conditions and solutions. , ... Whitaker, MD, a founder of the alternative health...pain.com, a new informational Web site devoted to ...
(Date:7/2/2009)...sts at Singapore,s Bioprocessing Technology Instit...e gene, "Fas-apoptosis inhibitory molecule" (FAIM)...sis, or programmed cell death. , Their research...nd Differentiation . , The scientists, Jianxin H...that this process may possibly be manipulated for ...
(Date:7/2/2009)...MYERS, Fla., July 2 Ace...-counter and prescription medicines to help reliev...taminophen by a brand name, Tylenol and prescripti...dvisory committee for the FDA met on June 30, 2009...of acetaminophen. The committee voted 20-17 to ur...
(Date:7/2/2009)... Health one of 63 businesses honored in Washington...e-USNewswire/ -- Texas Health Resources has rece...ward from the National Business Group on Health. ,...h/20090702/DC41773LOGO ) , , The award recog...tive programs that promote a healthy workplace and...
Breaking Medicine News(10 mins):Health News:Dr. Julian Whitaker Featured on Searchjointpain.com 2Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3
...d by Dr. Michael Brent, an associate professor of ...t. Louis, gives us an insight into the way childre...age.These findings were presented at the annual me...ancement of science in San Francisco.For years the...
... of the world, San Francisco is now reeling under ...tion. In the past one-year the rate of infection h...ct high-risk pockets of gay men, who are also intr...higher. And what is the cause for this sudden spur...
...lled the TAT vaccine has been developed in Italy a.... And more importantly it has had a 71% success ra...dy for human testing and this may be the brightest...e HIV. Dr.Barbara Ensoli, Head of the Department o...
...d patients, apart from suffering the social neglec...ve this major handicap - they just can’t travel li...ver they want. Some people just avoid having HIV i...t. Leaving the ethical issues aside, it is very di...
Other Medicine News:
(Date:7/2/2009)...OODCLIFF LAKE, N.J., July 2 Eisai ...O: Haruo Naito, "Eisai") and Eisai Corporation of ...hairman and CEO Hajime Shimizu) are currently focu...e company,s major product Aricept(R) (donepezil hy...ents with Alzheimer,s disease. As progress in thos...
(Date:6/30/2009)...June 30 Accumetrics, Inc. announce...ents) in the enrollment of its landmark clinical t... V erifyNow(R) Assay I mpact on T hrombosis A n...o demonstrate the value of providing clinicians wi...r responders to clopidogrel (Plavix(R)). The mult...
(Date:6/29/2009)...Minn., June 29 Pioneer...eness of deep brain stimulation (DBS) in hard-... (OCD) and Tourette,s syndrome are underway at mul...to a review in the June 2009 issue of Mayo Cl...ong been seen as valuable for controlling movement...
(Date:6/28/2009)...DE DO CORONADO, Portugal, June 29 ...hat add-on treatment with the novel,once-daily a...; ESL) resulted,in a marked and sustained decreas... Results from the one-year extension of a pivo...presented at the International Congress for Epilep...
Breaking Medicine Technology:Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value 2Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value 3Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 2Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 1Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 2Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 3Message to Tucson Residents 3A Forgo Fad Dieting and Join the Campaign for Healthy Weight 18175 4Cardica Intuitive Surgical MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium 18171 1Cardica Intuitive Surgical MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium 18171 2Cardica Intuitive Surgical MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium 18171 3Cardica Intuitive Surgical MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium 18171 4Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008 18167 1Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008 18167 2Baxa Announces Colorado BioScience Association Sponsorship 5033 1Baxa Announces Colorado BioScience Association Sponsorship 5033 2Baxa Announces Colorado BioScience Association Sponsorship 5033 3
...f stainless steel with the proven antibacterial pr...ed copper-alloy-stainless interior that is sterile...nvironment promotes the integrity of samples, vali... This exclusive SANYO copper stainless steel alloy...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres
...ine pH, mV (ORP), relative mV and temperature meas...e obtained when used with a temperature probe (ATC..., two- and three-point calibration with Auto-Find ...1.68, 4.00, 7.00, 10.01 and 12.45) and Auto-Read f...
...of system for pH, mV (ORP), relative mV, concentra...re compensated pH results can be obtained when use...rode. Up to five custom buffers are supported. &bu...32 interface to connect to a printer or a computer...
Medicine Products: